TY - JOUR
T1 - Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCORD-3)
T2 - analysis of individual data from 258 cancer registries in 61 countries
AU - CONCORD Working Group
AU - Ssenyonga, Naomi
AU - Stiller, Charles
AU - Nakata, Kayo
AU - Shalkow, Jaime
AU - Redmond, Sheilagh
AU - Bulliard, Jean Luc
AU - Girardi, Fabio
AU - Fowler, Christine
AU - Marcos-Gragera, Raphael
AU - Bonaventure, Audrey
AU - Saint-Jacques, Nathalie
AU - Minicozzi, Pamela
AU - De, Prithwish
AU - Rodríguez-Barranco, Miguel
AU - Larønningen, Siri
AU - Di Carlo, Veronica
AU - Mägi, Margit
AU - Valkov, Mikhail
AU - Seppä, Karri
AU - Wyn Huws, Dyfed
AU - Coleman, Michel P.
AU - Allemani, Claudia
AU - Bouzbid, Sabiha
AU - Hamdi-Chérif, Mokhtar
AU - Kara, Lamia
AU - Meguenni, Kaouel
AU - Regagba, Derbali
AU - Bayo, Sine
AU - Cheick Bougadari, Traore
AU - Manraj, Shyam Shunker
AU - Bendahhou, Karima
AU - Ladipo, Akinade
AU - Ogunbiyi, Olufemi
AU - Somdyala, Nontuthuzelo
AU - Chaplin, María Agustina
AU - Moreno, Florencia
AU - Calabrano, Gladis
AU - Espinola, Silvia
AU - Carballo Quintero, Beatriz
AU - Fita, Rosalba
AU - Laspada, Walter
AU - Ibañez, Susana
AU - Lima, Carlos
AU - Mafra Da Costa, Allini
AU - De Souza, Paulo César
AU - Chaves, Juliana
AU - Laporte, Cyntia
AU - Curado, Maria Paula
AU - de Oliveira, Jose Carlos
AU - Keinan-Boker, Lital
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2022/6
Y1 - 2022/6
N2 - Background: Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0–14 years) and adults (aged 15–99 years) diagnosed with a haematological malignancy during 2000–14 in 61 countries. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0–24 years). Methods: We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. We grouped patients by age as children (0–14 years), adolescents (15–19 years), and young adults (20–24 years). We categorised leukaemia subtypes according to the International Classification of Childhood Cancer (ICCC-3), updated with International Classification of Diseases for Oncology, third edition (ICD-O-3) codes. We estimated 5-year net survival by age and morphology, with 95% CIs, using the non-parametric Pohar-Perme estimator. To control for background mortality, we used life tables by country or region, single year of age, single calendar year and sex, and, where possible, by race or ethnicity. All-age survival estimates were standardised to the marginal distribution of young people with leukaemia included in the analysis. Findings: 164 563 young people were included in this analysis: 121 328 (73·7%) children, 22 963 (14·0%) adolescents, and 20 272 (12·3%) young adults. In 2010–14, the most common subtypes were lymphoid leukaemia (28 205 [68·2%] patients) and acute myeloid leukaemia (7863 [19·0%] patients). Age-standardised 5-year net survival in children, adolescents, and young adults for all leukaemias combined during 2010–14 varied widely, ranging from 46% in Mexico to more than 85% in Canada, Cyprus, Belgium, Denmark, Finland, and Australia. Individuals with lymphoid leukaemia had better age-standardised survival (from 43% in Ecuador to ≥80% in parts of Europe, North America, Oceania, and Asia) than those with acute myeloid leukaemia (from 32% in Peru to ≥70% in most high-income countries in Europe, North America, and Oceania). Throughout 2000–14, survival from all leukaemias combined remained consistently higher for children than adolescents and young adults, and minimal improvement was seen for adolescents and young adults in most countries. Interpretation: This study offers the first worldwide picture of population-based survival from leukaemia in children, adolescents, and young adults. Adolescents and young adults diagnosed with leukaemia continue to have lower survival than children. Trends in survival from leukaemia for adolescents and young adults are important indicators of the quality of cancer management in this age group. Funding: Children with Cancer UK, the Institut National du Cancer, La Ligue Contre le Cancer, Centers for Disease Control and Prevention, Swiss Re, Swiss Cancer Research foundation, Swiss Cancer League, Rossy Family Foundation, US National Cancer Institute, and the American Cancer Society.
AB - Background: Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0–14 years) and adults (aged 15–99 years) diagnosed with a haematological malignancy during 2000–14 in 61 countries. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0–24 years). Methods: We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. We grouped patients by age as children (0–14 years), adolescents (15–19 years), and young adults (20–24 years). We categorised leukaemia subtypes according to the International Classification of Childhood Cancer (ICCC-3), updated with International Classification of Diseases for Oncology, third edition (ICD-O-3) codes. We estimated 5-year net survival by age and morphology, with 95% CIs, using the non-parametric Pohar-Perme estimator. To control for background mortality, we used life tables by country or region, single year of age, single calendar year and sex, and, where possible, by race or ethnicity. All-age survival estimates were standardised to the marginal distribution of young people with leukaemia included in the analysis. Findings: 164 563 young people were included in this analysis: 121 328 (73·7%) children, 22 963 (14·0%) adolescents, and 20 272 (12·3%) young adults. In 2010–14, the most common subtypes were lymphoid leukaemia (28 205 [68·2%] patients) and acute myeloid leukaemia (7863 [19·0%] patients). Age-standardised 5-year net survival in children, adolescents, and young adults for all leukaemias combined during 2010–14 varied widely, ranging from 46% in Mexico to more than 85% in Canada, Cyprus, Belgium, Denmark, Finland, and Australia. Individuals with lymphoid leukaemia had better age-standardised survival (from 43% in Ecuador to ≥80% in parts of Europe, North America, Oceania, and Asia) than those with acute myeloid leukaemia (from 32% in Peru to ≥70% in most high-income countries in Europe, North America, and Oceania). Throughout 2000–14, survival from all leukaemias combined remained consistently higher for children than adolescents and young adults, and minimal improvement was seen for adolescents and young adults in most countries. Interpretation: This study offers the first worldwide picture of population-based survival from leukaemia in children, adolescents, and young adults. Adolescents and young adults diagnosed with leukaemia continue to have lower survival than children. Trends in survival from leukaemia for adolescents and young adults are important indicators of the quality of cancer management in this age group. Funding: Children with Cancer UK, the Institut National du Cancer, La Ligue Contre le Cancer, Centers for Disease Control and Prevention, Swiss Re, Swiss Cancer Research foundation, Swiss Cancer League, Rossy Family Foundation, US National Cancer Institute, and the American Cancer Society.
UR - http://www.scopus.com/inward/record.url?scp=85135760177&partnerID=8YFLogxK
U2 - 10.1016/S2352-4642(22)00095-5
DO - 10.1016/S2352-4642(22)00095-5
M3 - Article
C2 - 35468327
AN - SCOPUS:85135760177
SN - 2352-4642
VL - 6
SP - 409
EP - 431
JO - The Lancet Child and Adolescent Health
JF - The Lancet Child and Adolescent Health
IS - 6
ER -